Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-08-04 02:02 UTC

BIOMED PULSE

Tuesday, August 4, 2026 — Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in DRC has now surpassed 2,100 confirmed cases and 828 deaths as of July 15, making it the most serious active outbreak on the planet right now. The overall mood: urgent on hemorrhagic fever, cautiously watchful on hantavirus, and modestly hopeful on a new metformin-aging trial now publishing results.

🦠 OUTBREAKS & VIRUSES

EBOLA (BUNDIBUGYO VIRUS) — DRC AND UGANDA

  • As of July 15, 2026, a cumulative 2,124 confirmed cases and 828 deaths have been reported from the DRC in the ongoing Bundibugyo virus disease (BVD) outbreak, which began in Mongbwalu Health Zone, Ituri Province. [1]
  • Cross-border transmission to Uganda remains active, with sustained spread across multiple health zones outside the outbreak's original epicenter after two months of escalation. [1]
  • The case fatality rate among confirmed cases is running near 39%, consistent with historical Bundibugyo virus outbreaks, which are less lethal than Zaire ebolavirus but more lethal than Tai Forest. [2]
  • The August 1 WHO Disease Outbreak News update describes the outbreak as "intensifying" with sustained transmission and continued geographic expansion beyond Ituri Province. [3]
  • CDC has mobilized an international Ebola response, enhanced airport screening at Washington-Dulles and Atlanta international airports, and is providing daily briefings. [4][5][6]

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • The fifth WHO Disease Outbreak News report (July 2, 2026) on the Andes hantavirus cluster linked to the cruise ship M/V Hondius confirmed ongoing cases following the initial May 2 notification of severe acute respiratory illness aboard the vessel. [7]
  • As of the fourth DON (May 28), additional confirmed cases beyond the initial two laboratory-confirmed and five suspected cases had been identified, with passengers and crew across multiple countries affected. [8]
  • CDC's last dedicated hantavirus response transcript was published June 24, 2026, indicating ongoing monitoring; Andes hantavirus spreads person-to-person and causes hantavirus pulmonary syndrome with high fatality potential. [9]

CYCLOSPORA — TACO BELL, FIVE U.S. STATES

  • Shredded iceberg lettuce served at Taco Bell locations in five states was confirmed as the source of a cyclosporiasis outbreak, with 1,644 people sickened as of July 17, 2026. [10]
  • The outbreak was subsequently expanded to four additional states as of July 24, 2026, making it one of the largest single-source Cyclospora outbreaks on U.S. record.
  • CDC held a dedicated cyclosporiasis response briefing on July 14, 2026; Cyclospora cayetanensis is a parasitic pathogen typically linked to imported fresh produce.

WEST NILE VIRUS — UNITED STATES

  • CDC reported an early and record-pace West Nile virus season as of July 1, 2026, urging Americans to protect against mosquito bites during the July 4 holiday weekend.

NIPAH VIRUS — KERALA, INDIA

  • WHO confirmed one laboratory-confirmed Nipah virus (NiV) infection in an adult male in Kozhikode district, Kerala, India, on June 11, 2026; the patient presented with neurological symptoms after onset on May 30.
  • Kozhikode has been the repeated site of NiV spillover events; the natural reservoir is Pteropus fruit bats, and the case fatality rate in Kerala outbreaks has ranged from 40 to 100 percent.

YELLOW FEVER — GLOBAL

  • WHO reported 79 human yellow fever infections across six countries in the Americas and Africa from January 1 to May 26, 2026, following elevated transmission activity throughout 2025.

AVIAN INFLUENZA A(H9N2) — ITALY

  • Italy's IHR Focal Point notified WHO on March 21, 2026, of a human H9N2 case in an adult male returning from Senegal; next-generation sequencing confirmed influenza A(H9N2).
  • H9N2 is a low-pathogenicity avian influenza subtype that nonetheless poses pandemic risk due to its wide poultry reservoir and prior gene-segment donations to H5N1 and H7N9.

MEASLES — BANGLADESH

  • Bangladesh notified WHO on April 4, 2026, of a nationwide measles surge affecting 58 of 64 districts across all eight divisions; 19,161 suspected cases and 2,897 laboratory-confirmed cases were reported.

MPOX — RECOMBINANT CLADE Ib/IIb STRAIN, GLOBAL

  • WHO's February 14, 2026, Disease Outbreak News confirmed two cases of a recombinant monkeypox virus (MPXV) strain comprising genomic elements of both clade Ib and clade IIb, a novel combination arising through co-infection of a single individual.
  • Recombination between MPXV clades had not been widely documented in prior outbreaks; the event raises concern about whether novel hybrid strains could show altered transmissibility or immune escape.

🧬 LONGEVITY & AGING

EMERIN, TAU, AND NUCLEAR AGING IN NEURONS

  • A study published in Nucleus (Europe PMC, July 2026) by Sohn, Pardo, Molleur et al. finds that the mechanically sensitive nuclear envelope protein emerin is elevated in tau-affected neurons and links nuclear mechanotransduction to tau-driven cytoskeletal remodeling.
  • The finding connects two major threads in Alzheimer's biology — nuclear lamina dysfunction and tau pathology — suggesting the nucleus itself mechanically senses and responds to cytoskeletal changes driven by toxic tau aggregates.

COLLAGEN XVII AND EPIDERMAL STEM CELL PHOTOAGING

  • Wang X, Li Q et al. (Annals of Medicine, July 2026) show that recombinant human collagen XVII protects epidermal stem cells from blue light-induced photoaging by downregulating the Notch signaling pathway.
  • Blue light from screens and LED sources is an increasingly studied non-UV aging stressor; collagen XVII is a key hemidesmosome component that anchors epidermal stem cells and declines with age.

TELOMERE REPAIR, PML BODIES, AND LAMIN B1 IN CANCER SENESCENCE

  • Salmina K, Rumnieks F, Pjanova D et al. (Nucleus, July 2026) document repair and misrepair of telomeric DNA in doxorubicin-treated cancer cells, mapping dynamic interactions with PML nuclear bodies and lamin B1.
  • Misrepair at telomeres can drive senescence or genomic instability; PML bodies and the nuclear lamina are emerging as critical hubs for fate decisions after DNA damage.

P16-INK4A ANTIBODY VALIDATION IN PANCREAS SENESCENCE RESEARCH

  • Pipella J and Thompson PJ (Islets, July 2026) highlight critical problems with antibody validation for detecting the senescence marker p16-INK4A by immunohistochemistry in pancreatic tissue, cautioning that inconsistent antibodies may be distorting the field's picture of beta-cell senescence.
  • p16-INK4A is one of the most-used biomarkers of cellular senescence; inaccurate detection could lead researchers to over- or under-estimate senescent beta-cell burden in type 1 and type 2 diabetes.

LYSOSOMAL AMPK ACTIVATION FOR FATTY LIVER DISEASE

  • Zhu J, Sun T et al. (Bioactive Materials, July 2026) report that targeting ROAM1 with UDP-GlcNAc nanosheets selectively activates lysosomal AMPK to resolve metabolic dysfunction-associated steatotic liver disease (MASLD) in preclinical models.
  • Lysosomal AMPK activation is a distinct signaling node from cytosolic AMPK; this nanosheet approach offers a potential strategy to treat MASLD, which is now the most common chronic liver disease globally and strongly associated with accelerated aging.

METFORMIN FOR PHYSICAL FUNCTION IN OLDER ADULTS WITH OBESITY — DEMFOS TRIAL

  • Nava MLD, Viola V, Aguilar M et al. published the DEMFOS randomized controlled trial in Lancet Healthy Longevity, showing that metformin added to lifestyle intervention affected physical function outcomes in older adults with obesity.
  • An accompanying editorial by Witham MD and McDonald C cautions against "inflated expectations" for adjunctive metformin in aging-related frailty, noting the trial's nuanced findings.
  • This is a significant data point for the broader geroscience field testing metformin as a geroprotector, preceding the larger TAME (Targeting Aging with Metformin) trial.

IFN-ALPHA, DNA DAMAGE, AND STRESS RESPONSES IN HUMAN ISLETS

  • Akbari Motlagh R et al. (Islets, July 2026) find that IFN-alpha and bleomycin-induced DNA damage activate distinct stress-response programs in human islets versus iPSC-derived islet cells, with implications for understanding beta-cell aging and destruction in type 1 diabetes.

SOCIAL AND MEDICAL DETERMINANTS OF HEALTHY LONGEVITY

  • Amonova DS, Osmonova NI et al. publish a comprehensive analysis in Problemy Sotsialnoi Gigieny of challenges and prevention strategies for healthy longevity, examining how medical and social determinants interact to shape lifespan outcomes at the population level.

💊 NEW CURES & APPROVALS

QLONILIK (CLONIDINE HYDROCHLORIDE) — CMP DEV LLC

  • QLONILIK, a new original application (NDA 221094) for clonidine hydrochloride by sponsor CMP Dev LLC, received an FDA approval action (ORIG AP), representing a novel branded formulation of the established alpha-2 adrenergic agonist.
  • Clonidine is used for hypertension, ADHD, and off-label for conditions including opioid withdrawal management; the new NDA suggests a distinct formulation or indication from existing products.

VEKLURY (REMDESIVIR) — GILEAD SCIENCES INC

  • Gilead Sciences received a supplemental approval (SUPPL AP) for Veklury (remdesivir, NDA 214787), the antiviral approved for COVID-19 and other indications; details of the new supplement were not specified in the source data.

MYCOPHENOLATE FORMULATIONS — MULTIPLE SPONSORS

  • Multiple supplemental approvals were processed for mycophenolate mofetil and mycophenolate sodium formulations from sponsors including Roche Palo (CellCept, NDA 050759, NDA 050758), Hikma (ANDA 065410), Apotex (ANDA 091558), Alkem Labs, Accord Healthcare, Yichang Humanwell, Rising, Concord Biotech, and Azurity (Myhibbin, NDA 216482).
  • Mycophenolate is a key immunosuppressant used in transplant rejection prophylaxis and autoimmune conditions; multiple generic and brand supplements suggest ongoing manufacturing or labeling updates across the supply chain.

METFORMIN HYDROCHLORIDE — SUN PHARMACEUTICAL INDUSTRIES

  • Sun Pharmaceutical Industries received a supplemental approval for Metformin Hydrochloride (ANDA 077124), the first-line type 2 diabetes drug also under intensive investigation as a longevity agent.

🧪 CLINICAL TRIALS

METFORMIN IN OLDER ADULTS — DEMFOS TRIAL (PUBLISHED)

  • NCT not separately listed but results of the DEMFOS randomized controlled trial of metformin added to lifestyle intervention for physical function in older adults with obesity were published in Lancet Healthy Longevity; sponsor Nava MLD et al. conducted this multi-site study.

MIRDAMETINIB PLUS SIROLIMUS FOR RAS-MUTATED RELAPSED/REFRACTORY MULTIPLE MYELOMA

  • NCT06876142 is an active trial combining mirdametinib (MEK inhibitor) and sirolimus (mTOR inhibitor) for patients with KRAS- and NRAS-mutated relapsed/refractory multiple myeloma, registered as of August 3, 2026.
  • Dual MEK/mTOR blockade targets the RAS pathway at two nodes; KRAS and NRAS mutations are found in a significant fraction of myeloma patients who have exhausted standard therapies.

MRNA-1982 LYME DISEASE VACCINE — PHASE 1/2

  • NCT07561294 is evaluating safety, reactogenicity, and immunogenicity of Moderna's monovalent mRNA-1982 vaccine to prevent Lyme disease in healthy adults aged 18 to 70 years, registered August 3, 2026.
  • An mRNA-based approach to Lyme disease would be a major advance over the discontinued OspA-based LYMErix; tick-borne disease ER visits are running above seasonal norms in 2026 per CDC data.

TRITADENO VACCINE PLUS IL-15 SUPERAGONIST N-803 IN PROSTATE CANCER ACTIVE SURVEILLANCE

  • NCT07574541 is testing a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine (TriAdeno) combined with IL-15 superagonist N-803 in men with clinically localized prostate cancer on active surveillance, registered August 3, 2026.
  • The trial targets 35% of low-grade prostate cancer patients who progress to needing treatment within five years; the combined immunotherapy aims to induce immune-mediated tumor control.

NEXT-GENERATION INFLUENZA VACCINES IN OLDER ADULTS — LONGITUDINAL STUDY

  • NCT05518500 is a prospective single-arm study enrolling 75 adults aged 65 and older to receive three different influenza vaccines longitudinally, with the goal of understanding mechanisms of vaccine immune senescence in aging.

HPP737 FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS — TWO PARALLEL TRIALS

  • NCT07712731 and NCT07712705 are two concurrent trials evaluating HPP737 in adult patients with moderate-to-severe plaque psoriasis, comparing it to both active control and placebo at Week 16, registered August 3, 2026.

COLLAGEN AND OMEGA-3 SUPPLEMENTS IN MIDDLE-AGED WOMEN

  • NCT07740967 is examining the effects of combined collagen and omega-3 dietary supplements on joint pain, skin, and wellbeing outcomes in middle-aged women, reflecting a growing evidence base for targeted nutritional supplementation in aging.

SPIRONOLACTONE FOR ALCOHOL USE DISORDER — SAUD TRIAL

  • NCT05807139 is evaluating spironolactone, a mineralocorticoid receptor antagonist, as a treatment for alcohol use disorder (AUD) in a population of approximately 29.5 million affected U.S. adults, based on animal data showing reduced alcohol craving.

📢 PUBLIC HEALTH

E. COLI — FROZEN BLUEBERRIES

  • CDC posted a food safety alert on July 7, 2026, warning of an E. coli outbreak linked to frozen blueberries and advising consumers not to eat the recalled product.

INFANT BOTULISM — NARA ORGANICS INFANT FORMULA

  • CDC urged parents on June 13, 2026, to immediately stop using Nara Organics Whole Milk Organic Infant Formula following confirmation of its link to an ongoing infant botulism outbreak; this is the first documented infant botulism outbreak linked to powdered infant formula.

INFANT FORMULA — CEREULIDE TOXIN, MULTI-COUNTRY

  • WHO's March 2026 Disease Outbreak News reported multi-country recalls of infant formula and other products after cereulide toxin (produced by Bacillus cereus) was detected in batches linked to contaminated arachidonic acid (ARA) oil used as an ingredient.

NEW WORLD SCREWWORM — CDC EMERGENCY OPERATIONS CENTER ACTIVATED

  • CDC activated its Emergency Operations Center on June 12, 2026, for New World Screwworm (Cochliomyia hominivorax) response, a parasitic fly whose larvae infest living tissue and which had not been present in the continental U.S. since eradication in 1966.

CDC DIRECTOR SWORN IN

  • Susan Monarez, Ph.D., was sworn in as CDC Director on July 31, 2026, by HHS Secretary Robert F. Kennedy Jr., under the "Make America Healthy Again" agenda.

TIMOR-LESTE CERTIFIED MALARIA-FREE BY WHO

  • WHO certified Timor-Leste malaria-free on July 23, 2025, recognizing a sustained national elimination effort launched after the country's independence in 2002.

U.S. WHO WITHDRAWAL COMPLETED

  • The United States completed its withdrawal from the World Health Organization on January 22, 2026; WHO stated the decision "makes both the United States and the world less safe."

This briefing is informational only and does not constitute medical advice. All data sourced from CDC, WHO, openFDA, ClinicalTrials.gov, and Europe PMC as of 2026-08-04 02:00 UTC.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  5. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  6. Transcript - Update on Ebola Outbreak in the Democratic Republ… — CDC Newsroom
  7. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  8. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  9. Transcript - Update on CDC's Hantavirus Response - 6/24/26 — CDC Newsroom
  10. Shredded iceberg lettuce served at Taco Bell locations is sour… — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260804-02-v48 · 2026-08-04 02:02 UTC · pulse.uzylab.com

Read next